Search Results
28 protocol(s) meet the specified criteria
100517Open  
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone, Relative to Placebo plus Abiraterone plus Prednisone/Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

100769Open  
Phase II Open-Label Single-Arm Study of Adjuvant Nivolumab following Chemo-Radiation in localized Muscle-Invasive Bladder Cancer (NEXT)

101274Open  
Phase I Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects with Advanced Solid Tumors likely to Express Prolactin Receptor (PRLR)

101588Open  
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

101708Open  
PCCTC c16-168: BRCAAway: Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone plus Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

102312Open  
Phase II Study of Radium-223 and Radiotherapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone

102829Open  
Phase IB Dose-Escalation Study of Cabozantinib Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

103492Open  
Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-20 versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer

104258Open  
Phase I/II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

104935Open  
Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (Hyport) versus Conventional Post-Prostatectomy Radiation Therapy (Coport)

105691Open  
Nonpharmacologic Interventions for Fatigue in Patients with Cancer

105905Open  
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib in Combination with Physician's Choice of Enzalutamide or Abiraterone Acetate/Prednisone in Metastatic Castration-Resistant Prostate Cancer with DNA Damage Repair Deficiencies

43948Open  
Multi-Tracer PET Assessment of Response in Various Malignancies in Investigational and Recently Approved Therapeutic Agents

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

80887Open  
Randomized Phase II Study Comparing Bipolar Androgen Therapy versus Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response, and Modulates Enzalutamide Resistance)

81405Open  
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

82831Open  
Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

88485Open  
Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-Line Chemotherapy in Patients with Metastatic Urothelial Cancer

90642Open  
Phase I, Dose-Finding, and Signal-Seeking Study of the Safety and Efficacy of Intravenous Cavataktm Alone and in Combination with Pembrolizumab in Patients with Late Stage Solid Tumours (NSCLC and Bladder Cancer)

91746Open  
Phase I/II Open-Label, Dose-Escalation, Safety and Activity Study of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC)

92311Open  
Phase II Trial of Pembrolizumab in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)

92539Open  
Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma (PAPMET)

97382Open  
Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

97469Open  
Single-Arm, Multicenter, Phase II Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination with Everolimus in Subjects with Unresectable Advanced or Metastatic Non-Clear-Cell Renal Cell Carcinoma (nccRCC) who have not Received any Chemotherapy for Advanced Disease

98021Open  
Phase II Study of Brentuximab Vedotin and Bevacizumab in Refractory CD-30 Positive Germ Cell Tumors

98317Open  
Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and have Homologous Recombination Repair Gene Mutations (PROfound)

99128Open  
Open-Label Phase I/IIA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer

99182Open  
Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer